Lisa Ricciardi, President and CEO of Cognition Therapeutics, was recently a guest on Benzinga's All-Access.
Cognition Therapeutics is a neuroscience company that is developing oral medications to treat neurodegenerative disorders, with recent breakthroughs in the treatment of dementia with Lewy bodies (DLB) and Alzheimer's disease.
Ms. Ricciardi was on the program to discuss exciting developments coming in 2025.
